The account argues the scale of tirzepatide's sales gives Eli Lilly room to buy into and build entirely new areas of drug development.
Recap by typeshit. Post by On The Pen™ on X.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
A running page from GoodRx following how insurers are handling coverage for GIP and GLP-1 drugs this year.
The investor piece cites retatrutide's 28.3% mean weight loss in an 80-week Phase 3 study and Lilly's push into combo and maintenance dosing.
Loading…